Vaginal Micronized Progesterone in Treating Endometrial Hyperplasia Without Atypia

Abstract

Aim: In this study, we aimed to evaluate the efficacy of vaginal micronized progesterone (VMP) therapy in the treatment of endometrial hyperplasia without atypia by comparing it with levonorgestrel intrauterine device (LNG-IUD) therapy.

Material and Methods: This retrospective study included 133 premenopausal females with endometrial hyperplasia without atypia. The patients were divided into two groups according to VMP (n = 68, 200 mg once a day, 10 days/cycle) and LNG-IUD (n = 65) treatments. The groups were compared in terms of endometrial thickness measurements, endometrial sampling results, and hemoglobin (Hb) and hematocrit (Hct) values before and after treatment.

Results: Regression rates (90.8% with LNG-IUS vs. 88.2% with VMP; p = 0.601) and endometrial thickness values (4.5 mm with LNG-IUS, 5 mm with VMP, p = 0.382) were similar between the groups. A significant increase was observed in the VMP group in terms of blood parameters (Hb, Hct) after treatment (p < 0.05).

Discussion: VMP is as effective as LNG-IUD in treating hyperplasia without atypia.